Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Monoclonal antibodies such as cetuximab can locate tumor cells and
either kill them or deliver tumor-killing substances to them without harming normal cells.
Combining chemotherapy with cetuximab may kill more tumor cells.
PURPOSE: This randomized phase II trial is studying giving irinotecan and docetaxel together
with cetuximab to see how well it works compared to irinotecan and docetaxel alone in
treating patients with metastatic pancreatic cancer .